Latest News
Conference Coverage
Experts highlight recent breakthroughs in psoriatic arthritis
Signal of possible gender disparity in PsA response to biologics sparks questions.
Conference Coverage
To improve psoriatic arthritis outcomes, address common comorbidities
Depression and obesity are associated with poor treatment response in PsA.
Conference Coverage
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
News
Synovial, skin gene expression differences may explain PsA treatment responses
Different expression of genes in the synovial tissue and skin in people with psoriatic arthritis may affect their response to treatment.
Conference Coverage
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis
“The guidelines don’t give full credit to the anti–IL-17 agents.”
News
Guselkumab improvements for psoriatic arthritis persist through 1 year
Results extend previously published 24-week DISCOVER-2 data showing significant improvement over placebo.
News
Pregnancy studies on psoriasis, PsA medications pick up
OTIS has enrolled women with psoriasis and/or psoriatic arthritis in studies of nine medications, most of them biologics.
Article
Psoriasis, PsA, and pregnancy: Tailoring treatment with increasing data
Two experts give their up-to-date views on managing psoriasis and psoriatic arthritis before, during, and after pregnancy.
Conference Coverage
Biologics may delay psoriatic arthritis, study finds
A single-center study shows reduced incidence in psoriatic arthritis in psoriasis patients treated with biologics.
Conference Coverage
Psoriatic disease inflammation linked to heart failure
Psoriatic disease itself appears to contribute to heart failure risk rather than only comorbid cardiovascular risk factors.